• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Vyome Holdings Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits

    12/23/25 4:10:49 PM ET
    $HIND
    Medical/Dental Instruments
    Health Care
    Get the next $HIND alert in real time by email
    false 0001427570 0001427570 2025-12-17 2025-12-17 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, DC 20549

     

    FORM 8-K

     

    CURRENT REPORT

    Pursuant to Section 13 or 15(d) of the

    Securities Exchange Act of 1934

     

    Date of report (Date of earliest event reported): December 17, 2025

     

    VYOME HOLDINGS, INC.

    (Exact name of registrant as specified in its charter)

     

    Delaware   1-37897   26-1828101
    (State or other jurisdiction
    of incorporation)
      (Commission File Number)   (IRS Employer
    Identification No.)

     

    Harvard Square, One Mifflin Place, Suite 400
    Cambridge, MA
      02138
    (Address of principal executive offices)   (Zip Code)

     

    Registrant’s telephone number, including area code: (973) 832-8147

     

    Not Applicable

    (Former name or former address, if changed since last report)

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

     

    ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

     

    ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

     

    ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

     

    ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

     

    Securities registered pursuant to Section 12(b) of the Act:

     

    Title of each class   Trading Symbol(s)   Name of each exchange on which registered
    Common stock, par value $0.001 per share   HIND   The Nasdaq Capital Market

     

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

     

    Emerging growth company ☒

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     

     

     

     

     

    Item 1.01 Entry into a Material Definitive Agreement

     

    Letter of Intent with LICH and Remus:

     

    On December 17, 2025, Vyome Holdings, Inc. (the “Company”) entered into a binding letter of intent (the “LOI”) among, the Company, LiveChain, Inc. (“LICH”) and Remus Capital Series B II, L.P. (“Remus”). , regarding a proposed transaction pursuant to which LICH, an indirect subsidiary of the Company, agreed to execute definitive agreements to acquire a senior secured convertible note (the “Note”) issued by Sociometric Solutions, Inc., d/b/a Humanyze (“Humanyze”) and held by Remus in exchange for the issuance to Remus of shares of common stock of LICH.

     

    Under the LOI, LICH agreed to form a subsidiary (“Newco Sub”), which will enter into a Note Purchase and Exchange Agreement with Remus to acquire the Note. As consideration, LICH will issue to Remus shares representing 25% of the fully diluted common stock of LICH immediately prior to closing. An additional 10% of LICH’s common stock will be reserved for issuance to key and future employees of LICH, such that current LICH shareholders are expected to own 65% of LICH post-closing of the transaction.

     

    Remus agreed to ensure that Humanyze remains active and in good standing for purposes of servicing select existing debts, liabilities, and other obligations. Remus will have the right to appoint one director to the LICH board immediately after closing. The LICH board and CEO will use their best efforts to raise capital as needed. As a condition to closing of the transaction, LICH agreed to pay a good faith deposit of $20,000 to be remitted directly to Humanyze in lieu of Remus.

     

    Under the LOI, the parties agreed to use commercially reasonable efforts to execute definitive agreements within 30 days of the execution of the LOI and to consummate the transaction within an additional 45 days following satisfaction of all conditions to closing.

     

    The LOI and the transactions contemplated thereunder constitute a related party transaction. Accordingly, the LOI was reviewed and approved by the Audit Committee of the Board of Directors of the Company prior to its execution. Mr. Krishna K. Gupta (founder and CEO of Remus) and Mr. John Tincoff (a partner of Remus) recused themselves from the Audit Committee’s deliberations with respect to the LOI. The LOI was also reviewed and approved by the Company’s Board of Directors prior to its execution. Mr. Krishna K. Gupta (founder and CEO of Remus), Mr. Stash Pomichter (a partner of Remus) and Mr. John Tincoff (a partner of Remus) recused themselves from the Board of Directors’ deliberations with respect to the LOI.

     

    The description above is a summary of the principal terms of the LOI and does not constitute a complete description of all terms. The terms contained in the LOI are binding and are subject to the execution of definitive agreements and closing conditions being met.

     

    The foregoing description of the LOI is qualified in its entirety by reference to the full text of the LOI, a copy of which is attached hereto as Exhibit 10.1 and is incorporated herein in its entirety by reference.

     

    Item 9.01 Financial Statements and Exhibits

     

    Exhibit No.   Description
    10.1   Binding Letter of Intent, dated December 17, 2025, by and among Vyome Holdings, Inc., LiveChain, Inc., and Remus Capital Series B II, L.P.
    104   Cover Page Interactive Data File (embedded within the Inline XBRL document)

     

    1

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

      VYOME HOLDINGS, INC.
       
    December 23, 2025 By: /s/ Venkat Nelabhotla
      Name:  Venkat Nelabhotla
      Title: President & Chief Executive Officer

     

    2

     

    Get the next $HIND alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $HIND

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $HIND
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Vyome Presents Transformational VT-1953 Phase 2 Clinical Study Data at Prestigious AACR 2026

    VT-1953 topical gel significantly reduced MFW-associated severe malodor over a 14 Day period (P=0.0020) as scored by investigators. VT-1953 efficacy was significantly superior to the vehicle control (P= 0.0015). 70% of patients treated with VT-1953 vs 0% of patients treated with vehicle (control arm) reported an improvement in patient-reported outcome measure of impact of malodor on life by Day 14 (P= 0.0256). Patients treated with VT-1953 reported a clinically significant 2 point improvement in lesion pain by Day 14 (p= 0.0020) as scored using a 10-point VAS scale. No change seen in vehicle-treated arm. No treatment-emergent adverse effects were reported in this Phase 2 study.

    4/22/26 8:00:00 AM ET
    $HIND
    Medical/Dental Instruments
    Health Care

    Vyome to Present Compelling Phase 2 Clinical Data on VT-1953 for Treatment of MFW at AACR 2026

    Complete Phase 2 clinical data on the efficacy and safety of VT-1953 in MFW patients accepted for presentation at the annual meeting of the American Association for Cancer Research Vyome Holdings, Inc. ("Vyome") (NASDAQ:HIND) today announced that the company will present its full Phase 2 investigator initiated study results and preclinical data supporting the efficacy and safety of VT-1953 as a potential treatment for malodor and other symptoms of Malignant Fungating Wounds ("MFW") at the 2026 American Association for Cancer Research (AACR) Annual Meeting, taking place on April 17-22, 2026, in San Diego. Venkat Nelabhotla, CEO of Vyome, stated that, "There are currently no FDA approved

    4/6/26 8:00:00 AM ET
    $HIND
    Medical/Dental Instruments
    Health Care

    Vyome Reports Transformational 2025 Results: Company Well Positioned for Breakout Phase

    Completed a streamlined Nasdaq listing through a merger transaction, with a common stock capital structure and no preferred stock or debt Delivered positive final Phase 2 results for VT-1953 in treating symptoms of malignant fungating wounds, in line with expectations Independent valuation consulting firm, Destum Partners, valued VT-1953 at approximately $1 billion after a successful pivotal study Disciplined, cost-efficient operations as Vyome burned less cash than expected, giving the company a cash runway expected to extend through mid 2027, taking it up to pivotal trial interim readouts Added a new CTO, SVP of Clinical Development, and Senior Medical Advisor, bringing Big P

    3/26/26 8:00:00 AM ET
    $HIND
    Medical/Dental Instruments
    Health Care

    $HIND
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Director Pomichter Stanley D Iii

    4 - Vyome Holdings, Inc (0001427570) (Issuer)

    11/19/25 4:10:06 PM ET
    $HIND
    Medical/Dental Instruments
    Health Care

    SEC Form 3 filed by new insider Pomichter Stanley D Iii

    3 - Vyome Holdings, Inc (0001427570) (Issuer)

    11/19/25 4:05:05 PM ET
    $HIND
    Medical/Dental Instruments
    Health Care

    Director Jolly Mohanjit was granted 454,456 shares (SEC Form 4)

    4 - Vyome Holdings, Inc (0001427570) (Issuer)

    11/18/25 6:45:47 PM ET
    $HIND
    Medical/Dental Instruments
    Health Care

    $HIND
    SEC Filings

    View All

    SEC Form DEF 14A filed by Vyome Holdings Inc.

    DEF 14A - Vyome Holdings, Inc (0001427570) (Filer)

    3/31/26 6:03:52 AM ET
    $HIND
    Medical/Dental Instruments
    Health Care

    SEC Form PRE 14A filed by Vyome Holdings Inc.

    PRE 14A - Vyome Holdings, Inc (0001427570) (Filer)

    3/20/26 4:56:33 PM ET
    $HIND
    Medical/Dental Instruments
    Health Care

    SEC Form 10-K filed by Vyome Holdings Inc.

    10-K - Vyome Holdings, Inc (0001427570) (Filer)

    3/18/26 6:38:57 AM ET
    $HIND
    Medical/Dental Instruments
    Health Care

    $HIND
    Leadership Updates

    Live Leadership Updates

    View All

    Vyome Appoints Renowned Medical Oncologist, Dr. Aditya Bardia, as Senior Medical Advisor to Guide the Development of MFW Program

    Dr. Bardia has led the clinical development and FDA approvals of multiple blockbuster drugs Vyome Holdings, Inc. ("Vyome") (NASDAQ:HIND), a clinical-stage healthcare holding company, today announced Dr. Aditya Bardia as Senior Medical Advisor to Vyome. In this consulting role, Dr. Bardia will guide the clinical development of Vyome's lead asset, VT-1953, for the treatment of symptoms of malignant fungating wounds (MFW), a debilitating condition in cancer patients for which approval is being targeted in 2026. "I am excited to work with Vyome team and guide the clinical development of VT-1953 for the treatment of symptoms of malignant fungating wound, a debilitating condition that can signi

    11/25/25 7:00:00 AM ET
    $HIND
    Medical/Dental Instruments
    Health Care

    Vyome Holdings Announces Results of Annual Shareholder Meeting

    All 3 Class I directors, formerly at MIT, are re-elected to the board until the 2028 annual meeting Vyome Holdings, Inc. ("Vyome") (NASDAQ:HIND) announced it held its annual shareholder meeting on October 28, 2025. All 3 Class I directors up for re-election – Krishna K. Gupta, Shiladitya Sengupta, and Stash Pomichter – were re-elected to serve on Vyome's board until the 2028 annual shareholder meeting, with 93% of the votes being cast in favor. "This vote of confidence from shareholders ensures that Vyome's strong, innovative DNA of MIT alums remains intact for years to come. None of the Independent board members is taking any cash compensation or any new equity grants (other than grants

    11/4/25 9:04:00 AM ET
    $HIND
    Medical/Dental Instruments
    Health Care

    Vyome Holdings Strengthens Leadership Team with Industry Veterans as it plans Pivotal Trial Studies

    Dr. Richard Fahrner and Dr. Tamara Agajanov add expertise in accelerated approvals Vyome Holdings, Inc. (NASDAQ:HIND), a clinical-stage healthcare holding company, today announced the appointment of Dr. Richard Fahrner as Chief Technology Officer and Dr. Tamara Agajanov, MD, as Senior Vice President – Clinical Development. Dr. Fahrner brings to Vyome over 25 years of experience in drug development, recently serving as the head of pharmaceutical development at Ra Pharmaceuticals, which was acquired by UCB in a $2.5B deal. He also served as a research and development leader at Catabasis, Pfizer, Sanofi and Gilead. Dr. Fahrner has been involved with the development of more than 17 approved

    9/9/25 8:30:00 AM ET
    $HIND
    Medical/Dental Instruments
    Health Care

    $HIND
    Financials

    Live finance-specific insights

    View All

    Vyome Reports Transformational 2025 Results: Company Well Positioned for Breakout Phase

    Completed a streamlined Nasdaq listing through a merger transaction, with a common stock capital structure and no preferred stock or debt Delivered positive final Phase 2 results for VT-1953 in treating symptoms of malignant fungating wounds, in line with expectations Independent valuation consulting firm, Destum Partners, valued VT-1953 at approximately $1 billion after a successful pivotal study Disciplined, cost-efficient operations as Vyome burned less cash than expected, giving the company a cash runway expected to extend through mid 2027, taking it up to pivotal trial interim readouts Added a new CTO, SVP of Clinical Development, and Senior Medical Advisor, bringing Big P

    3/26/26 8:00:00 AM ET
    $HIND
    Medical/Dental Instruments
    Health Care

    Vyome Holdings Announces Transformational First Quarter Following Nasdaq Listing

    (Quarter Ended September 30, 2025) Completed a streamlined Nasdaq listing, with a 100% common stock capital structure Delivered encouraging interim Phase 2 results for VT-1953 in treating symptoms of malignant fungating wounds, in line with expectations. Disciplined, cost-efficient operations as Vyome burned less cash than expected, giving the company a cash runway expected to extend through 2026, inclusive of clinical trials. Added a new CTO and SVP of Clinical Development, bringing Big Pharma backgrounds, deep drug-development expertise, and experience across multiple FDA-approved therapies. Launched AI strategy with the acquisition of MIT startup Oculo Vyome Holdings, I

    11/18/25 7:00:00 AM ET
    $HIND
    Medical/Dental Instruments
    Health Care

    Vyome Holdings Acquires MIT AI Spinout Oculo Health

    Launches business unit to create AI psychiatrist focused on reducing inflammation Vyome remains fully funded through 2026 to unlock value from core assets Vyome Holdings, Inc. (NASDAQ: HIND), a clinical-stage healthcare holding company, today announced it has acquired substantially all of the assets of Oculo, Inc., an AI startup launched at the Massachusetts Institute of Technology ("MIT"). Concurrent with this transaction, Vyome has launched a new business unit focused on using AI to tackle inflammation. This new business unit will leverage Oculo's assets to develop an AI psychiatrist trained on data from both the US and India, and will be overseen by a newly-formed Vyome Board of Dire

    9/29/25 7:00:00 AM ET
    $HIND
    Medical/Dental Instruments
    Health Care